Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Receivables (2016 - 2025)

STRATA Skin Sciences' Receivables history spans 14 years, with the latest figure at $3.5 million for Q3 2025.

  • For Q3 2025, Receivables changed N/A year-over-year to $3.5 million; the TTM value through Sep 2025 reached $3.5 million, changed N/A, while the annual FY2024 figure was $5.3 million, 18.31% up from the prior year.
  • Receivables for Q3 2025 was $3.5 million at STRATA Skin Sciences, down from $4.0 million in the prior quarter.
  • Across five years, Receivables topped out at $5.3 million in Q4 2024 and bottomed at $2.9 million in Q1 2021.
  • The 5-year median for Receivables is $3.8 million (2022), against an average of $3.9 million.
  • The largest YoY upside for Receivables was 109.7% in 2021 against a maximum downside of 11.07% in 2021.
  • A 5-year view of Receivables shows it stood at $3.4 million in 2021, then surged by 30.24% to $4.5 million in 2022, then fell by 0.69% to $4.4 million in 2023, then grew by 18.31% to $5.3 million in 2024, then plummeted by 33.3% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for SSKN's Receivables are $3.5 million (Q3 2025), $4.0 million (Q2 2025), and $5.0 million (Q1 2025).